18 April 2016 - Merck today announced that the U.S. FDA has granted breakthrough therapy designation to Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of patients with relapsed or refractory classical Hodgkin's lymphoma.

This is the fourth breakthrough therapy fesignation granted for Keytruda; it was previously granted breakthrough status for specific patients with advanced melanoma, advanced non-small cell lung cancer and advanced colorectal cancer.

For more details, go to: http://www.mercknewsroom.com/news-release/oncology-newsroom/merck-receives-breakthrough-therapy-designation-us-food-and-drug-admi